Last quarter (Q3 2025), Barinthus Biotherapeutics's total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q3, Barinthus Biotherapeutics's net income was $-14.57M. See Barinthus Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	$ 14.97M	$ 802.00K	$ 44.70M	$ 268.00K	$ 4.82M
Gross Profit	$ 14.97M	$ 802.00K	$ 44.70M	$ 268.00K	$ -9.57M
Operating Expenses	$ 82.94M	$ 84.72M	$ 48.74M	$ 45.49M	$ 10.48M
Depreciation and Amortization	$ 5.80M	$ 5.43M	$ 4.32M	$ 602.00K	$ 208.00K
EBITDA	$ -55.37M	$ -71.06M	$ 5.19M	$ -47.87M	$ -16.56M
Operating Income	$ -67.97M	$ -83.91M	$ -4.04M	$ -45.22M	$ -20.05M
Other Income/Expenses	$ 6.74M	$ 7.39M	$ 4.89M	$ -5.92M	$ 2.21M
Pretax Income	$ -61.23M	$ -76.52M	$ 850.00K	$ -51.14M	$ -17.84M
Net Income	$ -61.07M	$ -73.35M	$ 5.34M	$ -50.87M	$ -17.71M
Per Share Metrics
Basic EPS	$ -1.55	$ -1.91	$ 0.14	$ -1.37	$ -2.24
Diluted EPS	$ -1.55	$ -1.91	$ 0.14	$ -1.37	$ -2.24
Weighted Average Shares Outstanding	39.35M	38.39M	37.25M	37.19M	7.90M
Weighted Average Shares Outstanding (Diluted)	39.35M	38.39M	38.17M	37.19M	7.90M

Currency in USD

Barinthus Biotherapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing